Concepedia

Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japanese and non-Japanese patients

T Haba, Kazuharu Uchida, Akio Katayama, Yuichi Tominaga, Tetsuhiko Sato, Ii‐Sei Watanabe, Hiroshi Inagaki, Tsukasa Kimata, Ken Goto, K Morozumi,

Transplantation Proceedings · 2001 · 12 citations · 2 references

Concepts

PharmacyClinical PharmacokineticsPharmacokineticsKidney TransplantationRenal PharmacokineticsTransplant ImmunologyImmunosuppression In Kidney TransplantationPharmacokinetics In Renal ImpairmentRenal PharmacologyTransplant PharmacokineticsTransplant PharmacologyTransplant RejectionAcute Renal Allograft RejectionChimeric Monoclonal AntibodiesKidney Transplant PharmacotherapyMonoclonal Antibodies In TransplantationPharmacodynamic Biomarkers In TransplantationPharmacokinetics In TransplantationTransplantation

References

2

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients

Björn Nashan, Richard H. Moore, P L Amlot et al. · The Lancet · 1997 · 762 citations

Life Sciences, Immunology, Nephrology +15

REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2

Barry D. Kahan, P. R. Rajagopalan, Michael Hall · Transplantation · 1999 · 483 citations

Life Sciences, Immunology, Pharmacology +17